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BACTERIA AND METHOD FOR 
SYNTHESIZING FATTY ACIDS 
PRIOR RELATED APPLICATIONS 
2 
engineered microorganisms, in which fadR is overexpressed 
and sucC is also overexpressed. However, there is no 
teaching with regard to the production of fatty acid in this 
patent. 
5 U.S. Pat. No. 7,553,645 discloses a process for preparing 
This application is a National Phase filing under 35 U.S.C. 
§371 of International Application PCT/US2012/060471 
filed on Oct. 16, 2012 which claims priority to U.S. Provi-
sional Applications 61/548,005, filed Oct. 17, 2011, and 
61/548,399, filed Oct. 18, 2011. Each of these applications 
is incorporated by reference in its entirety for all purposes. 
L-amino acids using a genetically engineered or transformed 
microorganism, in which sucC is overexpressed. However, 
there is no teaching with regard to the production of fatty 
acid in this patent. 
10 U.S. Pat. No. 7,211,415 also discloses a process for 
producing L-amino acids by fermentation of genetically 
engineered microorganisms of the Enterobacteriaceae fam-
ily, in which sucC is overexpressed. However, there is no FEDERALLY SPONSORED RESEARCH 
STATEMENT 
This invention was made with government support under 
Grant No: EEC-0813570 awarded by the National Science 
Foundation. The government has certain right in the inven-
tion. 
15 teaching with regard to the production of fatty acid in this 
patent. 
FIELD OF THE INVENTION 
US20110195505 discloses a genetically engineered lac-
tobacillus for butanol production, in which deletion at fabZl 
results in 10% increase in total cell membrane saturated fatty 
20 acids. However, there is no teaching regarding the effect of 
fabZ overexpression on the production of fatty acids. 
The invention relates to a method of increasing the 
production of fatty acids by using genetically engineered 
microorganisms. 
BACKGROUND OF THE INVENTION 
US20080160585 and US20080038787 disclose a method 
of increasing the production oflysine from a microorganism, 
in which sucC is deregulated. However, no detail was 
25 disclosed as to what extent of deregulation is involved, such 
as overexpressed, reduced or inactivated, nor on how to 
achieve the deregulation. 
Increasing energy costs and environmental concerns have 
emphasized the need to produce sustainable renewable fuels 30 
and chemicals. Fatty acids are composed of long alkyl 
chains and represent nature's "petroleum," being a primary 
metabolite used by cells for both chemical and energy 
storage functions. These energy-rich molecules are today 
isolated from plant and animal oils for a diverse set of 35 
products ranging from fuels to oleochemicals. 
Whereas microbial fermentation processes for producing 
ethanol and related alcohol biofuels are well established, 
biodiesel (methylesters of fatty acids) is the major long 
chain product produced biologically, and it is almost exclu- 40 
sively derived from plant oils today. However, slow cycle 
times for engineering oil seed metabolism and the excessive 
accumulation of glycerol as a byproduct are two major 
drawbacks of deriving biodiesel from plants. Although most 
bacteria do produce fatty acids as cell envelope precursors, 45 
the biosynthesis of fatty acids is tightly regulated at multiple 
levels and large quantities are not made. Thus, the produc-
tion of fatty acids from bacteria has not yet reached the point 
where it is cost effective. 
The ability to produce free fatty acid at high yields and 50 
high rates by the metabolically engineered strains would 
provide an efficient framework to produce a large class of 
other derived products ( chemicals and biofuels) either bio-
logically or chemically. For example, as shown in FIG. 1, by 
introducing additional appropriate pathways, fatty acids can 55 
be converted to chemicals such as hydrocarbons, fatty 
alcohols, hydroxyl fatty acids, dicarboxylic acids etc. Like-
wise, the omega-end of the molecules can be modified by 
changing the starting precursors in the initial step of the fatty 
acid biosynthesis pathway (marked by white block arrows). 60 
Furthermore, the chain length of these molecules can be 
changed by using appropriate acyl-ACP thioesterases spe-
cific to a particular chain length, such as CS, ClO, C12 or 
C14. In addition, various molecules can also be tapped out 
at different points during the fatty acid elongation cycle. 65 
U.S. Pat. No. 7,759,094 discloses a method for the 
production of L-amino acids by fermentation of genetically 
US20060046288 discloses a mutant E. coli strain with 
increased succinic acid production, in which it has reduced 
activity offadR gene. However, no detail regarding the fadR 
gene or the regulation/mutation thereof is specifically dis-
closed. 
W02011116279 discloses hybrid ACP thioesterases, 
which can be combined with deletions in native fadD, and 
sucC. They also teach acidifying the medium to increase 
production of fatty acids. 
Therefore, there is a need in the art for a biological system 
of producing fatty acids that is more efficient and cost 
effective than heretofore realized. 
SUMMARY OF THE INVENTION 
The invention relates to the production of fatty acid by 
genetically engineered microorganisms, in particular to 
engineered microorganisms that produce large amounts of 
free fatty acids by virtue of the addition of, for example, a 
plant acyl-ACP thioesterase and manipulation of the tran-
scription factor(s) involved in the fatty acid biosynthesis 
and/or degradation pathways; a combination of these tran-
scription factor(s) together with one or more of selected 
gene(s) in the fatty acid synthesis pathway, fatty acid deg-
radation pathway or the central metabolic pathway. 
This invention will allow the production of free fatty acid 
with yield close to the maximum theoretical yield. As such, 
this invention will provide the necessary framework to 
produce many other products sharing or branching out from 
the fatty acid synthesis pathway economically. These prod-
ucts include hydrocarbons, fatty alcohols, hydroxy fatty 
acids, dicarboxylic acids etc. 
In more detail, the invention is one or more of the 
following: 
A genetically engineered bacteria for producing fatty 
acids, said bacteria comprising a genotype comprising: 
i) an overexpressed acyl ACP thioesterase (TE+); 
ii) one or more of overexpressed FabZ+, FadR+, or FabH\ 
iii) zero, one or more of llfadR, llsucC, llfabR, llfadD, 
llptsG; 
US 9,598,696 B2 
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with the proviso that said bacteria does not have a genotype 
of llfadD llsucC TE+. 
A genetically engineered bacteria for producing fatty 
acids, said bacteria comprising a genotype comprising: 
i) an overexpressed acyl ACP thioesterase (TE+); 
ii) one or more of overexpressed FabZ+, FadR+, or FabH\ 
iii) zero, one or more of llfadR, llsucC, llfabR, llfadD, 
llptsG; 
with the proviso that said bacteria is not fabA+ and does not 
have a genotype of llfadD llsucC TE+. 
A genetically engineered bacteria of genotype comprising 
i) llsucC Fabz+TE-; ii) llsucC MabR Fabz+TE-; iii) Fabz+ 
TE\ iv) llfabR FadR+TE\ or v) llsucC llfabR FadR+TE\ 
or llsucC FabZ-TE\ or llfadD llsucC Fabz+TE+. 
10 
4 
3. fabz+ acyl-ACP thioesterase+ 
4. fadR+ acyl-ACP thioesterase+ 
5. llsucC llfabR acyl-ACP thioesterase+ 
6. llfabR acyl-ACP thioesterase+ 
7. llfadR fabz+ acyl-ACP thioesterase+ 
8. llfabR fabz+ acyl-ACP thioesterase+ 
9. llfadD llsucC fabz+ acyl-ACP thioesterase+ 
10. MadD llsucC llfabR fabz+ acyl-ACP thioesterase+ 
11. llfadD fabz+ acyl-ACP thioesterase+ 
12. MadD fadR+ acyl-ACP thioesterase+ 
13. MadD llsucC llfabR acyl-ACP thioesterase+ 
14. MadD llfabR acyl-ACP thioesterase+ 
15. MadD llfadR fabz+ acyl-ACP thioesterase+ 
A genetically engineered bacteria comprising a genotype 15 16. MadD llfabR fabz+ acyl-ACP thioesterase+ 
17. MadD llfabR fadR+ acyl-ACP thioesterase+ selected from the group consisting of: 
1) llfadD llfabR acyl-ACP thioesterase+ 
2) llfadD llfabR fabz+ acyl-ACP thioesterase+ 
3) llfadD llfadR acyl-ACP thioesterase+ 
4) llfadD llfadR fabz+ acyl-ACP thioesterase+ 
5) MadD MadR MabR acyl-ACP thioesterase+ 
6) llfadD fabz+ acyl-ACP thioesterase+ 
7) llfadD fadR+ acyl-ACP thioesterase+ 
8) llfadD llsucC llfabR acyl-ACP thioesterase+ 
9) llfadD llsucC llfabR fabz+ acyl-ACP thioesterase+ 
10) llfadD llsucC llfadR acyl-ACP thioesterase+ 
11) llfadD llsucC llfadR fabz+ acyl-ACP thioesterase+ 
12) llfadD llsucC llfabR llfadR acyl-ACP thioesterase+ 
13) llfadD llsucC fabz+ acyl-ACP thioesterase+ 
14) llfadD llsucC fadR+ acyl-ACP thioesterase-
15) llfabR acyl-ACP thioesterase+ 
16) llfabR fabz+ acyl-ACP thioesterase+ 
17) llfadR acyl-ACP thioesterase+ 
18) llfadR fabz+ acyl-ACP thioesterase+ 
19) llfadR llfabR acyl-ACP thioesterase+ 
20) fabz+ acyl-ACP thioesterase+ 
21) fadR+ acyl-ACP thioesterase+ 
22) llsucC llfabR acyl-ACP thioesterase+ 
23) llsucC llfabR fabz+ acyl-ACP thioesterase+ 
24) llsucC llfadR acyl-ACP thioesterase+ 
25) llsucC llfadR fabz+ acyl-ACP thioesterase+ 
26) llfadD llsucC llfabR llfadR acyl-ACP thioesterase+ 
27) llfadD llsucC fabz+ acyl-ACP thioesterase+ 
28) llfadD llsucC fadR+ acyl-ACP thioesterase+ 
29) llfadD llfabR fadR+ acyl-ACP thioesterase+ 
30) llfabR fadR+ acyl-ACP thioesterase+ 
31) llfadD llsucC llfabR fadR+ acyl-ACP thioesterase+ 
32) llsucC llfabR fadR+ acyl-ACP thioesterase+ 
33) llfadD llptsG fabH+ acyl-ACP thioesterase+ 
34) llptsG fabH+ acyl-ACP thioesterase+ 
In another embodiment, every bacteria herein described 
with a null mutation ( e.g., llgene) can instead be Gene-. 
Thus, llfadD can be FadD-, llfadR can be fadR-, llfabR can 
be FabR-, llsucC can be Succ- and llptsG can be PtsG-, etc. 
20 
18. MabR fadR+ acyl-ACP thioesterase+ 
19. MadD llsucC llfabR fadR+ acyl-ACP thioesterase+ 
20. llsucC llfabR fadR+ acyl-ACP thioesterase+ 
Other embodiments provide a genetically engineered 
Enterobacteriaceae or Enterobacter comprising llfadD 
llsucC Fabz+ TE\ or llfadD llsucC llfabR Fabz+ TE\ or 
llfadD Fabz+ TE\ or llsucC Fabz+ TE+ or llsucC llfabR 
Fabz+ TE\ or Fabz+ TE+, or any of the herein described 
25 bacteria. In yet other embodiments, the invention can easily 
be transferred to any bacteria with an equivalent gene set, 
e.g., in Firmicutes, Actinobacteria, Spirochetes, Proteobac-
teria, Bacillus, Streptococcus, Lactobaccillus, Lactococcus, 
Citrobacter, Haemophilus, Actinomycetes, Cyanobacteria, 
30 Staphylococcus, Neisseria, Micrococcus, Aspergillus, Psue-
domonas, and the like. Since there are hundreds of com-
pletely sequenced bacterial genomes readily available (see 
en.wikipedia.org/wiki/List_of_sequenced_bacterial_ge-
nomes ), a person of ordinary skill in the art can easily 
35 confirm homologous gene sets by comparison, esp. using 
protein sequences, which diverge less than gene sequences 
in the prokaryotes. 
Methods of producing fatty acids are also provided, 
comprising culturing any genetically engineered bacteria as 
40 described herein in a culture medium under conditions 
effective for the production of fatty acids; and harvesting 
said fatty acids from said bacteria and/or the culture 
medium. Another embodiment comprises adding acetic acid 
to said culture medium and harvesting the fatty acids from 
45 said culture medium. 
Another method of producing fatty acids is provided, 
comprising culturing a genetically engineered bacteria in a 
culture medium under conditions effective for the produc-
tion of fatty acids; and harvesting said fatty acids from the 
50 microorganism and/or the culture medium, wherein the 
bacteria and the desired fatty acid profile are selected from 
the group consisting of those listed in Table 2. Alternatively, 
the bacteria and the fatty acid profile are selected from the 
group consisting of: 
Any one of the herein described bacteria, which produce 55 
at least 14% more fatty acid than having a control micro-
organism having llfadD plus TE+. Preferably, said bacteria 
produces at least 45% more fatty acid, or at least 65% more 
fatty acid and most preferred, at least 80% more fatty acid 
than having a control microorganism having llfadD plus 60 
TE+. 
Bacteria: 
L\.fadD L\.fabR TE+ 
L\.fadD L\.fadR TE' 
L\.fadD L\.fadR Fabz+ TE' 
L\.fadD FabA + TE+ 
Fatty Acid Profile: 
about 60% C16:1 
about 60% C14 
about 60% C14 
about 90% C16 
A genetically engineered bacteria for producing increased 
amounts of fatty acids over a control bacteria lacking said 
genotype, said bacteria comprising a genotype selected from 
the group consisting of: 
1. llsucC fabz+ acyl-ACP thioesterase+ 
2. llsucC llfabR fabz+ acyl-ACP thioesterase+ 
Acyl-acyl carrier protein (ACP) thioesterase (herein 
known as "TE") is an enzyme that terminates the intraplas-
65 tidial fatty acid synthesis by hydrolyzing the acyl-ACP 
intermediates and releasing free fatty acids to be incorpo-
rated into glycerolipids. In plants, these enzymes are clas-
US 9,598,696 B2 
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sified in two families, FatA and FatB, which differ in amino 
acid sequence and substrate specificity. Generally speaking, 
the N terminal (aa 1-98) of any acyl-ACP thioesterases 
controls the substrate specificity of the enzyme, and it is 
known how to change substrate specificity by swapping 5 
amino terminal domains. 
6 
Diploknema butyracea (AAX51636.1), Cuphea palustris 
(AAC49180.1), or Gossypium hirsutum (AAF02215.1 or 
AF076535.1), or an overexpressed hybrid acyl-ACP thio-
esterase comprising different thioesterase domains operably 
fused together (see W02011116279, sequences expressly 
incorporated by reference herein). Preferably, the hybrid 
thioesterase includes an amino terminal region (-aa 1-98 
controls substrate specificity) of the acyl-ACP thioesterase 
from Ricinus communis or a 70, 80, 90 or 95% homolog 
thereto, or any TE with the desired substrate specificity, 
operably coupled to the remaining portion of the thioesterase 
from another species. In such mamier, enzyme specificity 
can be tailored for the use in question. 
In particular, the microorganism can comprise an over-
Bacteria already have native acyl-ACP thioesterase pro-
teins that can be used in the invention (e.g., FadM, TesA, 
TesB). These can be used as is, or up regulated or otherwise 
made to be overexpressed. However, any acyl-ACP thio- 10 
esterase can also be added to the bacteria, and this is 
especially beneficial where one wants to generate a specific 
distribution of fatty acids, since the various enzymes have 
different substrate preferences, some producing longer fats 
and others short fats. 15 expressed hybrid acyl-ACP thioesterase comprising the 
amino terminal region of the thioesterase from Ricinus 
communis operably coupled to the carboxyl region of the 
thioesterase from another species. Such microorganisms can 
be combined with each of the other knock-out and overex-
Many acyl-ACP thioesterase proteins are known and can 
be added to bacteria for use in the invention ( e.g., 
CAA52070, YP _003274948, ACY23055, AAB71729, 
BAB33929, to name a few of the thousands of such proteins 
available), although we have used plasmids encoding plant 20 
genes herein. Such genes can be added by plasmid or other 
vector, or can be cloned directly into the genome. In certain 
species it may also be possible to genetically engineer the 
endogenous protein to be overexpressed by changing the 
regulatory sequences or removing repressors. However, 25 
overexpressing the gene by inclusion on selectable plasmids 
that exist in hundreds of copies in the cell may be preferred 
due to its simplicity, although permanent modifications to 
the genome may be preferred in the long term for genetic 
stability. 
pressions described herein. 
As used herein, "enhanced amount" means>29% 
improvement in yield of fatty acids comparing to yield of 
fatty acids of the mutant strain ML103_18, which has 
inactivated fadD and overexpressed acyl-ACP thioesterase. 
Here the calculation of yield is determined by the ratio of 
grams of fatty acids produced to grams of glucose used. 
Preferably, >30, 35, 40, 45, 50, 60, 70 or 80% improvement 
is observed. 
Although certain strains have a reduced total amount of 
30 fatty acids, they may still be valuable as producing a 
particular distribution of fats, and thus even such strains are 
claimed herein. 
Other acyl ACP thioesterases include Umbellularia cali-
fornica fatty acyl-ACP thioesterase (AAC49001 ), Cinnamo-
mum camphora fatty acyl-ACP thioesterase (Q39473), 
Umbellularia californica fatty acyl-ACP thioesterase 
(Q41635), Myristica fragrans fatty acyl-ACP thioesterase 35 
(AAB71729), Myristica fragrans fatty acyl-ACP thio-
esterase (AAB71730), Elaeis guineensis fatty acyl-ACP 
thioesterase (ABD83939), Elaeis guineensis fatty acyl-ACP 
thioesterase (AAD42220), Populus tomentosa fatty acyl-
ACP thioesterase (ABC47311), Arabidopsis thaliana fatty 40 
acyl-ACP thioesterase (NP _172327), Arabidopsis thaliana 
fatty acyl-ACP thioesterase (CAA85387), Arabidopsis thali-
ana fatty acyl-ACP thioesterase (CAA85388), Gossypium 
hirsutum fatty acyl-ACP thioesterase (Q9SQI3), Cuphea 
lanceolata fatty acyl-ACP thioesterase (CAA54060), 45 
Cuphea hookeriana fatty acyl-ACP thioesterase 
(AAC72882), Cuphea calophylla subsp. mesostemon fatty 
acyl-ACP thioesterase (ABB71581), Cuphea lanceolata 
fatty acyl-ACP thioesterase (CACI 9933), Elaeis guineensis 
fatty acyl-ACP thioesterase (AAL15645), Cuphea hookeri- 50 
ana fatty acyl-ACP thioesterase (Q39513), Gossypium hir-
sutum fatty acyl-ACP thioesterase (AAD01982), Vitis 
vinifera fatty acyl-ACPthioesterase (CAN81819), Garcinia 
mangostana fatty acyl-ACP thioesterase (AAB51525), 
Brassica juncea fatty acyl-ACP thioesterase (ABI18986), 55 
Madhuca longifolia fatty acyl-ACP thioesterase 
(AAX51637), Brassica napus fatty acyl-ACP thioesterase 
(ABHll 710), Oryza sativa (indica cultivar-group) fatty 
acyl-ACP thioesterase (EAY86877), Oryza sativa (japonica 
cultivar-group) fatty acyl-ACP thioesterase (NP- 60 
001068400), Oryza sativa (indica cultivar-group) fatty acyl-
ACP thioesterase (EAY99617), and Cuphea hookeriana 
fatty acyl-ACP thioesterase (AAC49269). 
In some embodiments, at least one acyl-ACP thioesterase 
gene is from a plant, for example overexpressed acyl-ACP 65 
thioesterase gene from Ricinus communis 
(XP_002515564.1), Jatropha curcas (ABU96744.1), 
As used herein, "fatty acids" means any saturated or 
unsaturated aliphatic acids having the common formulae of 
CnH2n=COOH, wherein xsn, which contains a single car-
boxyl group. 
As used herein, "reduced activity" is defined herein to be 
at least a 7 5% reduction in protein activity, as compared with 
an appropriate control species. Preferably, at least 80, 85, 90, 
95% reduction in activity is attained, and in the most 
preferred embodiment, the activity is eliminated (100%). 
Proteins can be inactivated with inhibitors, by mutation, or 
by suppression of expression or translation, by knock-out, 
by adding stop codons, by frame shift mutation, and the like. 
By "knockout" or "null" mutant what is meant is that the 
mutation produces almost undetectable amounts of protein 
activity. A gene can be completely (100%) reduced by 
knockout or removal of part or all of the gene sequence. Use 
of a frame shift mutation, early stop codon, point mutations 
of critical residues, or deletions or insertions, and the like, 
can also completely inactivate (100%) gene product by 
completely preventing transcription and/or translation of 
active protein. All knockout mutants herein are signified by 
ti.gene where the gene name is identified above in Table A. 
As used herein, "overexpression" or "overexpressed" is 
defined herein to be at least 150% increase of protein activity 
as compared with an appropriate control species. Preferably, 
the activity is increased 200-500%. Overexpression can be 
achieved by mutating the protein to produce a more active 
form or a form that is resistant to inhibition, by removing 
inhibitors, or adding activators, and the like. Overexpression 
can also be achieved by removing repressors, adding mul-
tiple copies of the gene to the cell, or up-regulating the 
endogenous gene, and the like. All overexpressed genes or 
proteins are signified herein by "+". 
As used herein, all accession numbers are to GenBank 
unless indicated otherwise. 
US 9,598,696 B2 
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Exemplary gene or protein species are provided herein. 
However, gene and enzyme nomenclature varies widely, 
thus any protein ( or gene encoding same) that catalyzes the 
same reaction can be substituted for a named protein herein. 
Further, while exemplary protein sequence accession num-
bers are provided herein, each is linked to the corresponding 
DNA sequence, and to related sequences. Further, related 
sequences can be identified easily by homology search and 
requisite activities confirmed as by enzyme assay, as is 
shown in the art. 
E. coli gene and protein names (where they have been 
assigned) can be ascertained through ecoliwiki.net/ and 
enzymes can be searched through brenda-enzymes.info/. 
ecoliwiki.net/ in particular provides a list of alternate 
nomenclature for each enzyme/gene. Many similar data-
bases are available including UNIPROTKB, PROSITE; 5 
EC2PDB; ExplorEnz; PRIAM; KEGG Ligand; IUBMB 
Enzyme Nomenclature; IntEnz; MEDLINE; and MetaCyc, 
to name a few. 
By convention, genes are written in italic, and corre-
sponding proteins in regular font. E.g., fadD is the gene 
encoding FadD or acyl-CoA synthetase. 
5 
10 
15 
20 
Generally speaking, we have used the gene name and 
protein names interchangeably herein, based on the protein 25 
name as provided in ecoliwiki.net. The use of a protein name 
as an overexpressed protein (e.g, FabH+) signifies that 
protein expression can occur in ways other than by adding 
a vector encoding same, since the protein can be upregulated 
in other ways. The use of FadD- signifies that the protein can 30 
be downregulated in similar way, whereas the use of li.fadD 
means that the gene has been directly downregulated. 
The use of the word "a" or "an" when used in conjunction 
with the term "comprising" in the claims or the specification 
means one or more than one, unless the context dictates 35 
otherwise. 
The term "about" means the stated value plus or minus the 
margin of error of measurement or plus or minus 10% if no 
method of measurement is indicated. 
The use of the term "or" in the claims is used to mean 40 
"and/or" unless explicitly indicated to refer to alternatives 
only or if the alternatives are mutually exclusive. 
gene 
name 
fabZ 
fadD 
fadR 
sucC 
ptsG 
TE 
8 
TABLE A-continued 
Abbreviations and Definitions 
Definition (Protein name) 
Exemplary 
UNIPROTKB 
Acc. No. 
Gene that encodes a component of tbe POA6Q6 
complex 3R-hydroxymuristoyl acyl carrier 
protein (ACP) dehydratase (protein - FabZ) 
Gene that encodes acyl-CoA syntbetase P69451 
(protein - FadD) 
Gene that encodes DNA-binding POA8V6 
transcriptional dual regulator of fatty acid 
metabolism (protein - FadR) 
Gene that encodes succinyl-CoA syntbetase, POA836 
beta subunit (protein - SucC) 
Gene that encodes component of EIIGlc; P69786 
enzyme II glc; Glucose phophotransferase 
enzyme IIBC(Glc); glucose permease (PtsG) 
Any gene encoding an acyl ACP tbioesterase See tbroughout. 
(TE), not an assigned gene name, but used 
herein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Proposed metabolic map in which the introduction 
of additional appropriate pathways, the fatty acids can be 
converted to chemicals. 
FIG. 2. Simplified metabolic map showing the fatty acid 
synthesis pathway. The transcription factor FabR has shown 
to have negative effect on FabA and FabB; but the tran-
scription factor FadR has the opposite effect on FabA and 
FabB (Fujita et al., 2007). Free fatty acids are formed in the 
presence of an acyl-ACP thioesterase, which breaks the fatty 
acid elongation cycle. 
FIG. 3. Cell viability of strain MLK163_18Z, in which at 
least 75% of the cells are still viable after 48 hours growth. 
FIG. 4. Graphic illustrating that over 70% of the cellular 
content of the mutant strains are fatty acids. 
DESCRIPTION OF EMBODIMENTS OF THE 
INVENTION 
FIG. 2 shows a simplified central aerobic metabolic 
pathway of Escherichia coli using glucose, for example, as 
a carbon source. Also included in FIG. 1 are the fatty acid 
The terms "comprise", "have", "include" and "contain" 
(and their variants) are open-ended linking verbs and allow 
the addition of other elements when used in a claim. 
The phrase "consisting of' is closed, and excludes all 
additional elements. 
45 biosynthesis pathways. Note that each fatty acid elongation 
cycle will increase the carbon chain length of the fatty acid 
by two. Free fatty acids can be produced by introducing an 
acyl-thioesterase gene. The presence of the thioesterase will 
break the fatty acid elongation cycle and release free fatty The phrase "consisting essentially of' excludes additional 
material elements, but allows the inclusions of non-material 
elements that do not substantially change the nature of the 50 
invention. 
The following abbreviations are used herein: 
TABLE A 
Abbreviations and Definitions 
Exemplary 
gene UNIPROTKB 
name Definition (Protein name) Acc. No. 
fabA Gene tbat encodes beta-hydroxydecanoyl POA6Q3 
tbioester dehydrase (protein - FabA) 
fabB Gene tbat encodes 3-oxoacyl-[ acyl-carrier- POA953 
protein] syntbase (protein - FabB) 
fabH Gene tbat encodes 3-oxoacyl-[ acyl-carrier- POA6RO 
protein] syntbase III (protein - F abH) 
fabR Gene tbat encodes DNA-binding POACU5 
transcription repressor (protein - FabR) 
acids (Davis et al., 1993; Lu et al., 2008; Zhang et al., 2011). 
Also shown in FIG. 1 are the two transcription factors 
involved in the fatty acid biosynthesis and degradation 
pathways. The transcription factor FabR has shown to have 
negative effect on FabA and FabB; but the transcription 
factor FadR has the opposite effect on FabA and FabB 
55 (Fujita et al., 2007). 
Metabolically engineered strains were constructed based 
on the manipulation of the transcription factor( s) involved in 
the fatty acid biosynthesis and/or degradation pathways; a 
combination of these transcription factor(s) together with 
60 one or more of selected gene(s) in the fatty acid synthesis 
pathway, fatty acid degradation pathway or the central 
metabolic pathway. 
65 
Creating Strains 
The wild type E. coli strain was MG 1655 (F- lambda-
ilvG- rfb- rph- ATCC 47076). An fadD knockout was 
US 9,598,696 B2 
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introduced to make ML103 (MG1655 (MadD) (Zhang 
2011). The plasmid for overexpression was pTrc99a, a 
cloning vector from AMERSHAM PHARMACIA®, but 
any suitable vector could be used. 
In this work, we used acyl ACP thioesterase from castor 5 
bean, added by plasmid per our prior work. See Zhang 2011 
(pXZ18-pTrc99a carries an acyl-ACP thioesterase from 
Ricinus communis ( castor bean) (XM002515518). However, 
any suitable enzyme can be used, and many are available in 
suitable expression plasmids already. Another vector, 10 
pXZ18R, is the same gene in the plasmid pXZ18 but with 
the addition of a fadR gene from E. coli. 
The strains studied in the present invention are created 
based on a fadD knock-out mutant strain ML103_18, where 
the 18 is a particular clone number. We used the fadD mutant 15 
strain as a base strain because it is often used in the literature 
and easily available. However, deleting this gene is com-
pletely optional, and it is not considered a critical component 
of the genetic background. 
The mutational set includes knockouts of one or more of 20 
FadR, SucC, FabR, FadD together with wild type or over-
expressed acyl-ACP thioesterase together with overex-
pressed FabZ and FadR. The gene set should not include 
overexpressed FabA. 
25 
Knockout Wild type or 
mutations Overexpression Overexpression BUT Excluding 
Zero, TE+ from any one or more of Optionally FabA ••• 
one or more of species fabZ+, fadR +, L\.fadD L\.sucC 30 
L\.fadR, L\.sucC, or fabH+ acyl-ACP 
MabR, MadD, thioesterase+ 
L\.ptsG bacteria with no 
further mutations 
10 
used, and or the wild type gene could be upregulated. 
Further, while our gene sets included knockout mutations for 
simplicity and ease of interpreting results, knockout muta-
tions can be replaced with reduced activity mutations. 
Measuring Fatty Acid Production 
The metabolically engineered strains were studied in 
shake flasks. The strains were grown in 250 ml flasks, with 
40 ml Luria-Bertani (LB) broth medium supplemented with 
15 g/L of glucose, 1 mM IPTG, and appropriate amount of 
ampicillin. The cultures were grown in a rotary shaker at 250 
rpm. 
Samples of the media were taken at 24 and 48 hrs after 
inoculation. The fatty acids were analyzed and quantified by 
GC/MS and GC/FID after extraction. Odd number saturated 
straight chain fatty acids, such as C13, Cl 5 and/or Cl 7, were 
used as the internal standard. The results shown in the table 
are the sum of all major free fatty acids in the sample. The 
data shown are means for triplicate experiments at 48 hrs. 
ML163 from W02011116279 is very similar to 
MLKl 63 _18 (bold font in Table 1) and has the same genetic 
construction of li.fadD, li.sucC and acyl-ACP thioesterase+, 
though the MLK variant has a kanamycin marker. 
ML103_18 (bold font) was chosen as the base or control 
strain in this work, although a bacteria wild type for the gene 
set in question would also be a suitable control, and the 
improvement in fatty acids levels would be even higher. 
Some constructs do not give a yield higher than ML163_18 
(underlined in Table 1), a strain taught in earlier work. 
However, such strains may have other desirable properties, 
such as different fatty acid distribution and/or percentage 
excreted to the medium. Thus, such strains are included 
herein even though they may produce less fatty acid than 
**FabAis known to have negative effect when used with the full complement of mutations, 
but may be beneficial with certain subsets, and this is being tested. 
35 strain ML163_18. Further, such strains when compared 
While our overexpression constructs were made by add-
ing plasmid to a wild type background, this is not the only 
way to generate overexpression, and if desired the wild type 
gene can be completely replaced, other vectors could be 
against wild type bacteria probably have some level of 
improved production. 
From the results shown below in Table 1, positive effects 
were observed in the strains shaded grey, and the best 
producers are indicated with an arrow. 
TABLE 1 
Free fatty acid and yield (g of fatty acids produced/g of glucose used) 
Free % Yield % 
FA improve- (g FA/g improve-
Strain name Relevant genotype (g/1) ment* glucose) ment* 
ML103_18 L\.fadD acyl-ACP thioesterase+ 3.12 0.21 
US 9,598,696 B2 
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TABLE I-continued 
Free fatty acid and yield (g of fatty acids produced/g of glucose used) 
MLK213_18 i\.fadD i\.sucC MadR acyl-ACP 2.75 
thi oesterase + 
MLK213_18Z i\.fadD i\.sucC MadR fabZ+ acyl- 0.32 
ACP thioesterase + 
MLK228_18 i\.fadD i\.sucC MabR i\.fadR acyl- 3.24 
ACP thioesterase + 
MLK163_18A i\.fadD i\.sucC fabA+ acyl-ACP 2.03 
thi oesterase + 
fabA+ = overexpression ofFabA by plasmid, plus wild type gene present 
fabZ+ = overexpression ofFabZ by plasmid, plus wild type gene present; 
fadR + = overexpression of FadR by plasmid, plus wild type gene present 
-12 0.19 -10 
-90 0.06 -71 
4 0.21 0 
-35 0.17 -19 
acyl-ACP thioesterase + = overexpression of castor bean acyl ACP TE, plus wild type present. 
*percentage improvement based on ML103_18 
Inactivation of the transcription factor FabR improves 
fatty acid production and yield for both the parent strain and 
the sucC mutant strain (MLK211 vs ML103_18 and 
MLK212 vs MLK163_18). 
Overexpression of FabZ improves fatty acid production 
and yield for both the parent strain and the sucC mutant 
strain (ML103_18Z vs ML103_18 and MLK163_18Z vs 
MLK163_18). In fact, a combination of sucC inactivation 
and FabZ overexpression yield the best strain with a very 
high titer of 5.65 and a yield of 0.38 gig (which is 81 % 
improvement over the base strain ML103_18). The yield of 
Strain name 
MLK163 18Z 
MLK212 18Z 
ML103 18Z 
ML103 18fadR 
MLK163 18 
40 0.38 gig is very close to the maximum theoretical value (The 
maximum theoretical yields of C14 and C16 straight chain 
fatty acids are 0.3629 and 0.3561 gig, respectively). 
Overexpression of FadR improves fatty acid production 
and yield for the parent strain (ML103_18fadR vs 
45 ML103_18). 
Order of improvements: li.sucC fabZ+>li.sucC!i.fabR 
fabZ+>fabZ+>fadR+>li.sucC>li.sucC!i.fabR>MabR or MadR 
fabZ+>li.fabR fabz+. By extracting only those with positive 
results in Table 1, we have the following Table 1.1, wherein 
the balded strain MLK163-18 is similar to strain ML 163. 
TABLE 1.1 
Free fatty acid and yield of positive strains 
Free FA % improve- Yield % improve-
Relevant genotype (g/1) ment* (gig) ment 
i\.fadD i\.sucC fabz+ acyl-ACP 5.65 81 0.38 81 
thioesterase + 
i\.fadD i\.sucC i\.fabR fabz+ acyl- 5.15 65 0.34 62 
ACP thioesterase+ 
MadD fabz+ acyl-ACP 4.61 48 0.31 48 
thioesterase+ 
MadD fadR+ acyl-ACP 4.19 34 0.27 29 
thioesterase+ 
i\.fadD i\.sucC acyl-ACP 3.96 27 0.27 29 
thioesterase+ 
US 9,598,696 B2 
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TABLE I.I-continued 
Free fatty acid and yield of positive strains 
Free FA % improve- Yield % improve-
Strain name Relevant genotype (g/1) ment* (gig) ment 
MLK212 18 L\.fadD L\.sucC L\.fabR acyl-ACP 3.83 23 
thioesterase+ 
MLK211 18 L\.fadD MabR acyl-ACP 3.73 20 
thioesterase + 
MLK225 18Z L\.fadD MadR fabz+ acyl-ACP 3.71 19 
thioesterase+ 
MLK211 18Z L\.fadD MabR fabz+ acyl-ACP 3.62 16 
thioesterase + 
15 
Additionally, some negative effects have been observed in 
the following strains: 
0.26 24 
0.25 19 
0.25 19 
0.24 14 
that a selected single or selected combination of these 
manipulations is required to increase the yield and titer as 
shown in Table 2. Overexpression of FabA significantly decreases fatty acid 
production and yield for both the parent strain and the li.sucC 
mutant strain (ML103_18A vs MLK103 18 and 
MLK163_18A vs ML163_18). 
Simultaneous deactivation of FadR and FabR also 
decreases fatty acid production and yield for the 
(MLK227 _18 vs MLK103_18). 
Our invention also indicates that the long belief of the 
carboxylation of acetyl-CoA to malonyl-CoA is the limiting 
20 step of fatty acid biosynthesis may not necessarily be the 
case since we have constructed strains that can achieve high 
yield ( close to maximum theoretical yield), high titer and 
high production rate of free fatty acids. 
25 
Additional strains we have tested and gave very good 
results are MLK211(pXZ18R) and MLK212(pXZ18R)-
which are li.fadD li.fabR FadR+ acyl-ACP thioesterase+ and 
li.fadD li.sucC li.fabR FadR+ acyl-ACP thioesterase+. We are 
planning to test MadD li.fabR acyl-ACP thioesterase+ FadR+ 30 
Fabz+ and li.fadD li.sucC li.fabR acyl-ACP thioesterase+ 
FadR+ FabZ+, which we expect to give even better results. 
Distribution of Fatty Acids 
The genetic manipulations demonstrated herein also have 
significant effect on the distribution of the free fatty acids 
(Table 2). As such, this invention also will allow the manipu-
lation or tailoring of the type of fatty acids to be produced. 
For example, while the engineered strain ML103_18A can 
produce more than 88% of Cl 6, the other engineered strains 
MLK225_18 and MLK225_18Z can produce about 60% of 
C14, and MLK211_18 can produce about 60% of C16:1. As a result, it is clear that random overexpression or 
deletion of transcription factors and/or with genes in the 
fatty acid synthesis and central metabolic pathway may not 
necessarily lead to positive results. Our data demonstrated 
This indicates that the exact genetic combination has a 
35 significant effect on the fatty acid composition, even one 
uses the sanie acyl-ACP thioesterase. 
Strain name 
ML103 18 
MLK163 18 
MLK211 18 
MLK211 18A 
MLK211 18Z 
MLK225 18 
MLK225 18Z 
MLK227 18 
ML103 18A 
ML103 18Z 
ML103_18fadR 
MLK212 18 
MLK212 18A 
MLK212 18Z 
MLK213 18 
MLK213 18Z 
MLK228 18 
TABLE 2 
Fatty acid distribution (Percentage of total) 
Relevant genotype C14 
L\.fadD acyl-ACP tbioesterase• 47.27 
L\.fadD, L\.sucC acyl-ACP tbioesterase• 37.30 
L\.fadD L\.fabR acyl-ACP tbioesterase• 19.14 
L\.fadD L\.fabR fabA+ acyl-ACP 16.28 
thi oesterase + 
L\.fadD L\.fabR fabz+ acyl-ACP 45.62 
thi oesterase + 
L\.fadD L\.fadR acyl-ACP tbioesterase• 59.63 
L\.fadD L\.fadR fabz+ acyl-ACP 58.56 
thi oesterase + 
L\.fadD L\.fadR MabR acyl-ACP 48.40 
thi oesterase + 
L\.fadD fabA+ acyl-ACP tbioesterase• 10.92 
L\.fadD fabz+ acyl-ACP tbioesterase• 57.91 
L\.fadD fadR+ acyl-ACP tbioesterase• 18.29 
L\.fadD L\.sucC L\.fabR acyl-ACP 18.52 
thi oesterase + 
L\.fadD L\.sucC L\.fabR fabA+ acyl-ACP 11.91 
thi oesterase + 
L\.fadD L\.sucC LI. fabR fabz+ acyl-ACP 40.24 
thi oesterase + 
L\.fadD L\.sucC L\.fadR acyl-ACP 55.95 
thi oesterase + 
L\.fadD L\.sucC L\.fadR fabz+ acyl-ACP 44.58 
thi oesterase + 
L\.fadD L\.sucC L\.fabR L\.fadR acyl-ACP 38.26 
thi oesterase + 
C16:1 C16 C18:1 
38.33 12.96 1.45 
31.74 28.06 2.91 
59.12 17.50 4.24 
15.45 64.40 3.88 
25.51 74.41 2.83 
23.36 14.02 ND 
3.05 38.40 ND 
34.39 17.09 0.13 
0.00 89.08 ND 
8.16 33.92 ND 
48.09 26.85 6.77 
57.59 18.50 5.40 
10.33 76.32 1.44 
16.46 42.59 0.71 
27.05 16.31 0.69 
3.51 43.74 ND 
38.13 22.78 0.83 
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15 16 
TABLE 2-continued 
Fatty acid distribution (Percentage of total) 
Strain name Relevant genotype C14 C16:1 C16 C18:1 
MLK163 18A L\.fadD L\.sucC fabA+ acyl-ACP 20.95 7.50 71.55 ND 
thioesterase + 
MLK163 18Z L\.fadD L\.sucC fabz+ acyl-ACP 53.25 10.55 36.20 ND 
thioesterase+ 
MLK163 18fadR L\.fadD L\.sucC fadR+ acyl-ACP 14.24 38.39 35.78 11.59 
thioesterase + 
ND: Not detected 
synthesis enzymes and overexpressed acyl ACP thio-The super-producer strain MLK163_18Z (llfadD llsucC 
fabz+ acyl-ACP thioesterase-) was analyzed further by 
measuring the total cell dry weight. Samples were taken at 
16, 24 36 and 48 hours after inoculation and tested for cell 
viability using propidium iodide staining of DNA and flow 
cytometry. The results are shown in FIG. 3. 
15 esterases can significantly increase fatty acid production, to 
level heretofore not thought possible. Further, the distribu-
tion of fatty acids can be manipulated by introducing dif-
ferent combinations of mutations. In addition, the present 
invention shows that overexpression of fabH can result in 
It was found that at least more than 75% of the cells 
remained viable after 48 hrs. The dry weight of the sample 
at 48 hours was also determined and used to estimate the 
fraction of free fatty acid inside the cells. As explained in 
FIG. 4, certain amounts of free fatty acids are released from 
the cell, whereas a greater amount of free fatty acids are still 
located within the cells. It was found that free fatty acid 
accounts for more than 70% of the cellular contents. 
20 improvement of fatty acids production, at least in C-8 fatty 
acids. 
The following publications are incorporated by reference 
in their entirety for all purposes herein. 
Davies, H. M., et al., 1993. Fatty acid synthesis genes: 
25 Engineering the production of medium-chain fatty acids. p. 
176-181. In: J. Janick and J.E. Simon (eds.), New crops. 
Wiley, N.Y. 
FabH Overexpression 
It has been reported that FabH is involved in the initiation 
30 
Fujita Y, et al., Regulation of fatty acid metabolism in 
bacteria. Mo! Microbial. November 2007; 66(4):829-39. 
Lu, X., et al., 2008. Overproduction of free fatty acids in 
E. coli: Implications for biodiesel production. Metabolic 
Engineering. 10: 333-339. 
Zhang X, et al. 2011. Efficient free fatty acid production 
in Escherichia coli using plant acyl-ACP thioesterases 
35 Metabolic Engineering, Metab Eng. November 2011; 13(6): 
713-22. 
of fatty acid biosynthesis, and we propose that overexpres-
sion of FabH may also contribute to the production of fatty 
acids. To study the impact of the initiation step in the fatty 
acids synthesis pathway, another engineered strain 
ML190_88-fabH (MadD llptsG FabH+) carrying a modified 
acyl-ACP thioesterase from C. palustris (Acc. No. Q39554) 
specific to shorter chain length and with FabH from E. coli 
(UNIPROTKB Acc. No. POA6RO) overexpression was con- 40 
structed and tested in Super Broth (SB) medium with 30 g/L 
of glucose. The strain ML190_88 fabH s about 19% 
improvement in fatty acids production over the control strain 
ML190_88, as shown in Table 3. 
TABLE 3 
Free fatty acid (CS straight chain fatty acid) 
Free FA % improve-
Strain name Relevant genotype (CS) (g/1) ment* 
ML190 88 L\.fadD L\.ptsG acyl-ACP 1.08 
thioesterase+ 
ML190 88 fabH L\.fadD L\.ptsG fabH+ 1.28 19 
acyl-ACP thioesterase• 
fabH+ = overexpression of FabH by plasmid, plus wild type enzyme present 
45 
50 
55 
U.S. Pat. No. 7,759,094 
U.S. Pat. No. 7,553,645 
U.S. Pat. No. 7,211,415 
US20110195505 
US20080160585 
US20080038787 
US20060046288 
W02011116279 
Campbell J W, Cronan J E Jr. 2001. Escherichia coli FadR 
positively regulates transcription of the fabB fatty acid 
biosynthetic gene. J Bacterial. 183(20):5982-90. 
What is claimed is: 
1. A genetically engineered bacteria for producing fatty 
acids, said bacteria being Enterobacteriaceae and compris-
ing a genotype comprising: 
a) an overexpressed acyl ACP thioesterase (TE+); 
b) one or more of an overexpressed FabZ+, FadR+, or 
FabH+; 
c) one or more of a llfadR, llsucC, llfabR, llfadD, or 
llptsG; 
with the proviso that said bacteria does not have a 
genotype of llfadD llsucC TE+, 
wherein said bacteria produces at least 14% more fatty 
acid than having a control microorganism having 
MadD plus TE+. 
This result shows that with the same genetic background, 
overexpression ofFabH improves fatty acid production. We 
will also plan to add FabH to the strains of Table 1.1, 
beginning with the best producers, such as llfadD llsucC 60 
Fabz+ TE\ MadD llsucC MabR Fabz- TE\ and MadD 
Fabz+ TE+. Although not yet available, it is predicted that 
the combination with further improve fatty acid production 
levels, although the effect on distribution of fats is not yet 
known. 
2. The genetically engineered bacteria of claim 1, wherein 
the genotype of said bacteria comprises i) llsucC FabZ+ 
TE+; ii) llsucC MabR FabZ+ TE+; iv) MabR FadR+ TE+; 
65 or v) llsucC llfabR FadR+ TE+. 
The present invention shows that manipulating repressor 
levels along with overexpression of certain fatty acid bio-
3. The genetically engineered bacteria of claim 1, wherein 
the genotype of said bacteria comprises llsucC FabZ+ TE+. 
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4. The genetically engineered bacteria of claim 1, wherein 
the genotype of said bacteria comprises li.fadD li.sucC 
FabZ+ TE+. 
18 
( 4) fadR+ acyl-ACP thioesterase+ 
(5) li.sucC li.fabR acyl-ACP thioesterase+ 
(6) MabR acyl-ACP thioesterase-
5. The genetically engineered bacteria of claim 1, wherein 
the genotype of said bacteria comprises a genotype selected 5 
(7) MadR fabZ+ acyl-ACP thioesterase+ 
(8) MabR fabZ+ acyl-ACP thioesterase+ 
(9) li.fadD li.sucC fabZ+ acyl-ACP thioesterase+ from the group consisting of: 
(1) MadD MabR acyl-ACP thioesterase+ 
(2) MadD MabR fabZ+ acyl-ACP thioesterase+ 
(3) MadD MadR acyl-ACP thioesterase+ 
(4) MadD MadR fabZ+ acyl-ACP thioesterase+ 
(5) MadD MadR MabR acyl-ACP thioesterase+ 
(6) MadD fabZ+ acyl-ACP thioesterase+ 
(7) MadD fadR+ acyl-ACP thioesterase+ 
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(10) MadD li.sucC MabR fabZ+ acyl-ACP thioesterase+ 
(11) MadD fabZ+ acyl-ACP thioesterase+ 
(12) MadD fadR+ acyl-ACP thioesterase+ 
(13) MadD li.sucC MabR acyl-ACP thioesterase+ 
(14) MadD MabR acyl-ACP thioesterase+ 
(8) MadD li.sucC MabR acyl-ACP thioester~se+ 
15 (9) MadD li.sucC MabR fabZ+ acyl-ACP thioesterase+ 
(10) MadD li.sucC MadR acyl-ACP thioester~se+ 
(15) MadD MadR fabZ+ acyl-ACP thioesterase+ 
(16) MadD MabR fabZ+ acyl-ACP thioesterase+ 
(17) MadD MabR fadR+ acyl-ACP thioesterase+ 
(18) MabR fadR+ acyl-ACP thioesterase+ 
(11) MadD li.sucC MadR fabZ+ acyl-ACP t~oesterase+ 
(12) MadD li.sucC MabR MadR acyl-ACP th10esterase+ 
(13) MadD li.sucC fabZ+ acyl-ACP thioesterase+ 
(14) MadD li.sucC fadR+ acyl-ACP thioesterase+ 
(15) MabR acyl-ACP thioesterase+ 
(16) MabR fabZ+ acyl-ACP thioesterase+ 
(17) MadR acyl-ACP thioesterase+ 
(18) MadR fabZ+ acyl-ACP thioesterase+ 
(19) MadR MabR acyl-ACP thioesterase+ 
(21) fadR+ acyl-ACP thioesterase+ 
(22) li.sucC li.fabR acyl-ACP thioesterase+ 
(23) li.sucC MabR fabZ+ acyl-ACP thioesterase+ 
(24) li.sucC li.fadR acyl-ACP thioesterase+ 
(25) li.sucC MadR fabZ+ acyl-ACP thioesterase+ 
(26) MadD li.sucC MabR MadR acyl-ACP thioesterase+ 
(27) MadD li.sucC fabZ+ acyl-ACP thioesterase+ 
(28) MadD li.sucC fadR+ acyl-ACP thioesterase+ 
(29) MadD MabR fadR+ acyl-ACP thioesterase+ 
(30) MabR fadR+ acyl-ACP thioesterase+ 
(31) MadD li.sucC MabR fadR+ acyl-ACP thioesterase+ 
(32) li.sucC MabR fadR+ acyl-ACP thioesterase+ 
(33) MadD !i.ptsG fabH+ acyl-ACP thioesterase+ 
(19) MadD li.sucC MabR fadR+ acyl-ACP thioesterase+ 
(20) li.sucC MabR fadR+ acyl-ACP thioesterase+ 
(21) MadD li.ptsG fabH+ acyl-ACP thio~sterase+. . 
10. A genetically engineered Enterobactenaceae compns-
20 ing !i.fadD li.sucC FabZ+ TE+. . . 
11. A genetically engineered Enterobactenaceae compns-
ing MadD !i.sucC MabR FabZ+ TE+. . . 
12. A genetically engineered Enterobactenaceae compns-
ing MadD FabZ+ TE+. . . 
13. A genetically engineered Enterobactenaceae compns-25 
ing li.sucC FabZ+ TE+. . . 
14. A genetically engineered Enterobactenaceae compns-
ing !i.sucC MabR FabZ+ TE+. . .. 
15. A method of producing fatty acids, compnsmg cul-
30 turing a genetically engineered bacteria of any of claim 1-14 
in a culture medium under conditions effective for the 
production of fatty acids; and harvesting said fatty acids 
from said bacteria and/or the culture medium. 
16. The method of producing fatty acids of claim 15, 
35 comprising adding acetic acid to said culture medium and 
harvesting the fatty acids from said culture medium. 
(34) ti.ptsG fabH+ acyl-ACP thioesterase+.. . 
40 6. The genetically engineered bacteria of clmm 1, ~herem 
17. A method of producing fatty acids, comprising cul-
turing a genetically engineered bacteria in _a culture medi_um 
under conditions effective for the product10n of fatty acids; 
and harvesting said fatty acids from the microorganism 
and/or the culture medium, wherein the bacteria and the fatty 
said bacteria produces at least 45% more fatty acid than 
having a control microorganism having li.fac!J? plus TE+ .. 
acid profile are selected from the group consisting of those 
listed in Table 2. 
18. The method of claim 17, wherein the bacteria and the 
fatty acid profile are selected from the group consisting of: 
7. The genetically engineered bacteria of clmm 1, ~herem 
said bacteria produces at least 65% more fatty acid than 
having a control microorganism having li.fac!J? plus TE+.. 45 
8. The genetically engineered bacteria of clmm 1, ~herem -----------------------
said bacteria produces at least 80% more fatty acid than 
having a control microorganism having li.fadD plus TE:. 
9. A genetically engineered bacteria for producmg 
increased amounts of fatty acids, said bacteria being Entero-
bacteriaceae and comprising a genotype selected from the 
group consisting of: 
(1) li.sucC fabZ+ acyl-ACP thioesterase+ 
(2) li.sucC li.fabR fabZ+ acyl-ACP thioesterase+ 
50 
Bacteria: 
L\.fadD L\.fabR TE+ 
L\.fadD L\.fadR TE+ 
L\.fadD L\.fadR Fabz+ TE' 
L\.fadD FabA + TE+ 
* * 
Fatty Acid Profile: 
about 60% C16:1 
about 60% C14 
about 60% C14 
about 90% C16 
* * * 
